Ultrasensitive ctDNA Monitoring During CDK4/6 Inhibitor Therapy for Metastatic Breast Cancer
- We performed MRD monitoring using Myriad’s Precise MRD and show that this ultrasensitive approach is a promising tool for monitoring disease burden and treatment response in the setting of CDK4/6 inhibitor therapy for metastatic breast cancer
- The Precise MRD assay enabled 100% pre-CDK4/6i detection and identified 50/180 (28%) on-treatment samples with tumor fraction in the 1-100 parts per million range
- An early decrease in ctDNA levels was significantly associated with longer progression-free survival, and our results also demonstrate that ctDNA can distinguish between molecularly stable disease and molecular CR among patients with radiographic CR, highlighting its potential as a biomarker to guide treatment strategies in those with outstanding clinical responses